Clinical trials: Candidiasis, Invasive
Candidiasis, Invasive, Candidemia
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis including candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous…
- Trial name
- MARIO (NCT05178862)
- Testing
- SCY-078, Fluconazole, Echinocandin
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 68 people
- Sponsor
- Scynexis, Inc.
Candidemia
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against…
- Trial name
- NCT00839540
- Testing
- micafungin, Caspofungin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gary E. Stein, Pharm.D.
Mycoses
A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects
Subjects with intra-abdominal infection requiring surgery and Intensive Care Unit stay will be treated early with micafungin or placebo to determine the incidence and time to confirmation of fungal infection.
- Trial name
- INTENSE (NCT01122368)
- Testing
- micafungin
- Where
- 56 sites in Austria, Belgium and 13 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Inc
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
- Trial name
- DIRECT (NCT01525095)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- T2 Biosystems
Acute Myeloid Leukemia, Aspergillosis
Pre-hospital Risk Factors for Invasive Fungal Infection
SEIFEM 2010 study is a prospective, multicenter registry designed to identify and analyze risk factors for developing an invasive fungal infection in patients with newly diagnosed Acute Myeloid Leukemia, with particular interest…
- Conditions
- Acute Myeloid Leukemia, Aspergillosis, Candidiasis, Mycoses
- Trial name
- SEIFEM 2010 (NCT01315925)
- Where
- 42 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Catholic University of the Sacred Heart
Candidiasis
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
The purpose of this study is to investigate the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers.
- Trial name
- NCT00797420
- Testing
- Fluconazole Loading Dose, Fluconazole Loading Dose & High Dose
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Daniel Benjamin
Fungemia, Neutropenia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system.
- Conditions
- Fungemia, Neutropenia, Candidiasis
- Trial name
- NCT00806351
- Testing
- Active Anidulafungin, Active Caspofungin
- Where
- 10 sites in Bosnia and Herzegovina, France and 4 more
- Volunteers
- 21 people
- Sponsor
- Pfizer
Invasive Fungal Infection
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
The pharmacokinetics of caspofungin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine caspofungin concentrations in 20 ICU patients, who will get caspofungin as standard…
- Trial name
- CASCADE (NCT01533558)
- Testing
- caspofungin
- Where
- 4 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Invasive Candidiasis, Candidemia
Genetic Susceptibility Factors for Candidemia.
This is a prospective case-control physiopathological study, which main objective is to determine the genetic host factors predisposing to candidemia.
- Conditions
- Invasive Candidiasis, Candidemia, Genetic Predisposition to Disease
- Trial name
- NCT02841501
- Testing
- Analysis of genetic polymorphisms
- Where
- France
- Volunteers
- 453 people
- Sponsor
- University Hospital, Lille
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Candida, Candidiasis
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
Fluconazole is an FDA-approved drug that is widely used to treat fungal infections due to candida. The experimental drug anidulafungin has been found to be active in treating life-threatening fungal infections.
- Trial name
- NCT00058682
- Testing
- Anidulafungin
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Candidiasis
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
Invasive fungal infections (IFIs) are a frequent cause of morbidity and mortality in high-risk patients, such as immunocompromised patients.
- Trial name
- MI-K (NCT02164890)
- Testing
- micafungin
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Limoges
Candidiasis, Invasive, Candidemia
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida…
- Trial name
- CARES (NCT03363841)
- Testing
- SCY-078
- Where
- 12 sites in United States, India and 2 more
- Volunteers
- 30 people
- Sponsor
- Scynexis, Inc.
Candidemia
Echinocandins Versus Azoles for Candidemia Treatment
Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients.
- Trial name
- AntiCandiTreat (NCT03799172)
- Testing
- Echinocandin treatment, Triazole treatment
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Hospices Civils de Lyon
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Infection, Fungal
Dosage of Plasma 1, 3-β-D-glucan for the Diagnosis of Candidemia.
Systematic and repeated dosing (3 times weekly) of 1,3-β-D-glucan (BDG), associated with blood cultures and fungal mapping (twice a week) for the patients hospitalized in intensive care.
- Trial name
- BDG-REA (NCT03674359)
- Testing
- BDG analysis
- Where
- 2 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Candidiasis
NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Invasive Candida infections are serious complications in immunocompromised patients including those undergoing treatment for cancer but occur also in patients treated in ICUs.
- Trial name
- NOBICS (NCT02801682)
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Candidemia, Candidiasis
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp.
- Trial name
- NCT01982071
- Testing
- Micafungin
- Where
- 15 sites in China
- Volunteers
- 59 people
- Sponsor
- Astellas Pharma China, Inc.
Candidiasis
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs).
- Trial name
- NCT00083343
- Testing
- MK0991, caspofungin acetate/Duration of Treatment: variable
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC